Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Onco Targets Ther. 2013 May 14;6:527-30. doi: 10.2147/OTT.S44162. Print 2013.

Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer.

Author information

  • 1The First Affiliated Hospital of Xinxiang Medical University, Weihui, People's Republic of China.


One of the most important molecules mediating the proliferation, growth, and metastasis of cancer cells is insulin-like growth factor (IGF), with its receptor IGF-1R. Here, we describe the potential of an IGF-1R monoclonal antibody, HX-1162, on liver cancer apoptosis in vitro and in vivo. We found that HX-1162 could induce the apoptosis of cultured liver cancer cells. Additionally, HX-1162 treatment inhibited the tumor growth after cancer cell grafting and enhanced the cell apoptosis inside the tumor tissue. We conclude that IGF-1R targeting therapy provides a new avenue toward treating liver cancer.


IGF; IGF-1R; apoptosis; hepatocellular carcinoma

Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk